High-throughput screening approaches for investigating drug metabolism and pharmacokinetics
暂无分享,去创建一个
[1] J J Baldwin,et al. Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.
[2] D. Wu,et al. High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparation. , 1998, Rapid communications in mass spectrometry : RCM.
[3] Thomas J. Raub,et al. A General, Wide-Range Spectrofluorometric Method for Measuring the Site-Specific Affinities of Drugs toward Human Serum Albumin , 1995 .
[4] A M Richard,et al. Commercial toxicology prediction systems: a regulatory perspective. , 1998, Toxicology letters.
[5] I. Wilson,et al. Rapid multi-component detection of fluorinated drug metabolites in whole urine from a ‘cassette’ dose study using high resolution 19F NMR spectroscopy , 1999 .
[6] M D Todd,et al. Emerging technologies for accelerated toxicity evaluation of potential drug candidates. , 1999, Current opinion in drug discovery & development.
[7] M H Tarbit,et al. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.
[8] T. Olah,et al. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.
[9] Pravin Chaturvedi,et al. Design principles for orally bioavailable drugs , 1996 .
[10] M. Abraham,et al. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. , 1999, Journal of pharmaceutical sciences.
[11] D. Surry,et al. High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[12] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[13] A Tropsha,et al. Recent trends in computer-aided drug discovery. , 2000, Current opinion in drug discovery & development.
[14] W. Rubas,et al. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.
[15] W. Pardridge,et al. CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport , 1998, Journal of neurochemistry.
[16] M Pastor,et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] Crespi. Assessing the potential for drug-drug interactions in an accelerated throughput mode. , 1999, Pharmaceutical science & technology today.
[18] Peter C. Jurs,et al. Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure , 1998, J. Chem. Inf. Comput. Sci..
[19] R. Norton,et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. , 1998, JAMA.
[20] U Norinder,et al. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. , 1998, Journal of pharmaceutical sciences.
[21] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[22] P. Morgan,et al. Role of transport proteins in drug absorption, distribution and excretion , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[23] T. Andersson,et al. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. , 1999, The Journal of pharmacology and experimental therapeutics.
[24] J. Bolton,et al. Metabolic screening using on-line ultrafiltration mass spectrometry. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[25] Ada M. Herrera,et al. Microdialysis Sampling for Determination of Plasma Protein Binding of Drugs , 1990, Pharmaceutical Research.
[26] A. Li,et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.
[27] P. Woollard,et al. Cassette dosing: rapid in vivo assessment of pharmacokinetics , 1998 .
[28] B. W. Penman,et al. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.
[29] A. Beresford,et al. ADME/PK as part of a rational approach to drug discovery. , 2000, Drug discovery today.
[30] A. D. Rodrigues,et al. [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[31] S. Ball,et al. Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[32] Amess,et al. Proteomics: a major new technology for the drug discovery process. , 1999, Drug discovery today.
[33] S. Ekins,et al. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[34] S. Kliewer,et al. Use of the nuclear receptor PXR to predict drug interactions. , 2000, Toxicology.
[35] Johnson,et al. Predicting human safety: screening and computational approaches. , 2000, Drug discovery today.
[36] M. Gross,et al. Fourier transform mass spectrometry. , 1984, Science.
[37] F. Gonzalez,et al. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. , 1996, Molecular pharmacology.
[38] D. Livingstone,et al. Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. , 2000, European journal of medicinal chemistry.
[39] H Lennernäs,et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.
[40] C. Pidgeon,et al. IAM chromatography: an in vitro screen for predicting drug membrane permeability. , 1995, Journal of medicinal chemistry.
[41] H. Kusuhara,et al. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). , 2001, Drug discovery today.
[42] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[43] M Bajpai,et al. High-throughput screening for lead optimization: a rational approach. , 2000, Current opinion in drug discovery & development.
[44] Ferenc Darvas,et al. Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries , 2000, J. Chem. Inf. Comput. Sci..
[45] M K Bayliss,et al. High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.
[46] J Taskinen. Prediction of aqueous solubility in drug design. , 2000, Current opinion in drug discovery & development.
[47] D. Lewis,et al. A prospective toxicity evaluation (COMPACT) on 40 chemicals currently being tested by the National Toxicology Program. , 1990, Mutagenesis.
[48] F. Gonzalez,et al. Analysis of human cytochrome P450 catalytic activities and expression. , 1992, The Tohoku journal of experimental medicine.
[49] P Ruelle,et al. The hydrophobic effect. 2. Relative importance of the hydrophobic effect on the solubility of hydrophobes and pharmaceuticals in H-bonded solvents. , 1998, Journal of pharmaceutical sciences.
[50] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[51] Yukio Tominaga,et al. Comparative study of class data analysis with PCA-LDA, SIMCA, PLS, ANNs, and k-NN , 1999 .
[52] K. Adkison,et al. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. , 1997, Journal of medicinal chemistry.
[53] A. Monks,et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. , 1999, Biochemical pharmacology.
[54] Chao-pin Lee,et al. Selection of development candidates based on in vitro permeability measurements , 1997 .
[55] J B Houston,et al. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[56] H. Waterbeemd,et al. Comparison of passive drug transport through Caco-2 cells and artificial membranes , 1997 .
[57] B. W. Penman,et al. Development of Caco-2 Cells Expressing High Levels of cDNA-Derived Cytochrome P4503A4 , 1996, Pharmaceutical Research.
[58] A. Li,et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.
[59] U Norinder,et al. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[60] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[61] M H Tarbit,et al. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[62] R. Cooks,et al. Quadrupole Mass Filters and Quadrupole Ion Traps , 1997 .
[63] Ronald T. Borchardt,et al. Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides , 1994, Pharmaceutical Research.
[64] M. Hoshen,et al. The role of ligand-binding proteins in increasing the transcellular flux of metabolites, in particular that of calcium, bilirubin, and fatty acids , 1996 .
[65] B. Walther,et al. Rapid assessment of drug metabolism in the drug discovery process. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[66] Han van de Waterbeemd,et al. Estimation of Caco‐2 Cell Permeability using Calculated Molecular Descriptors , 1996 .
[67] G M Pacifici,et al. Methods of Determining Plasma and Tissue Binding of Drugs , 1992, Clinical pharmacokinetics.
[68] D. E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.
[69] D. Scarpelli,et al. Uptake of N-nitrosobis(2-oxopropyl)amine by isolated rat and hamster hepatocytes: species differences and evidence for an active carrier-mediated transport process. , 1988, Carcinogenesis.
[70] Grazyna D. Szklarz,et al. Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..
[71] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[72] C. Crespi. Higher-throughput screening with human cytochromes P450. , 1999, Current opinion in drug discovery & development.
[73] Y. Sugiyama,et al. Primary active transport of organic anions on bile canalicular membrane in humans. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[74] G. Caldwell. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. , 2000, Current opinion in drug discovery & development.
[75] S. L. Dixon,et al. LASSOO: a generalized directed diversity approach to the design and enrichment of chemical libraries. , 1999, Journal of medicinal chemistry.
[76] P. Veng‐Pedersen,et al. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. , 1994, Journal of pharmaceutical sciences.
[77] S. Walker,et al. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.
[78] Mark T. D. Cronin. Computer‐aided Prediction of Drug Toxicity in High Throughput Screening , 1998 .
[79] R. Plumb,et al. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. , 1998, Rapid communications in mass spectrometry : RCM.
[80] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[81] D. E. Clark,et al. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.
[82] C. Wolf,et al. Use of Transgenic Animals in Understanding Molecular Mechanisms of Toxicity * , 1998, The Journal of pharmacy and pharmacology.
[83] K. Hayashi,et al. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. , 1990, The Journal of biological chemistry.
[84] P A Carrupt,et al. Evaluation and Prediction of Drug Permeation , 1999, The Journal of pharmacy and pharmacology.
[85] R J Riley,et al. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[86] C. Hop,et al. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.
[87] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[88] K Gubernator,et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.
[89] Evans,et al. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.
[90] D. R. Hawkins,et al. Use and value of metabolism databases. , 1999, Drug discovery today.
[91] S. Fulton,et al. Ultrafiltration vs Equilibrium Dialysis for Determination of Free Fraction , 1984, Clinical pharmacokinetics.
[92] P J Sinko. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. , 1999, Current opinion in drug discovery & development.
[93] D. Robertson,et al. High-throughput toxicology: practical considerations. , 2000, Current opinion in drug discovery & development.
[94] B Testa,et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.
[95] R. S. Thomas,et al. Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. , 1998, Environmental health perspectives.
[96] J. Henion,et al. Sample preparation for LC/MS/MS: analyzing biological and environmental samples. , 1998, Analytical chemistry.
[97] P. Swaan,et al. Molecular determinants of recognition for the intestinal peptide carrier. , 1997, Journal of pharmaceutical sciences.
[98] G. Grass,et al. Simulation models to predict oral drug absorption from in vitro data , 1997 .
[99] R. A. Coleman,et al. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[100] G Folkers,et al. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[101] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[102] Walter A. Korfmacher,et al. HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .
[103] N. Olejnik,et al. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[104] L. Wienkers,et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[105] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[106] M. Tarbit,et al. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[107] C. Bevan,et al. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.
[108] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[109] T. Kennedy. Managing the drug discovery/development interface , 1997 .
[110] Walter A. Korfmacher,et al. Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability. , 1999, Rapid communications in mass spectrometry : RCM.
[111] Walter A. Korfmacher,et al. Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .
[112] A. Seelig. A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.
[113] A George. The design and molecular modeling of CNS drugs. , 1999, Current opinion in drug discovery & development.
[114] M H Tarbit,et al. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[115] Thomas A. Baillie,et al. The Impact of Drug Metabolism in Contemporary Drug Discovery: New Opportunities and Challenges for Mass Spectrometry , 2000 .
[116] B. Kennedy,et al. Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[117] P. Worboys,et al. Implications and consequences of enzyme induction on preclinical and clinical drug development , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[118] D. Egan,et al. Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. , 1993, Journal of medicinal chemistry.
[119] J. Tolan,et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.
[120] James L. Winkler,et al. Accessing Genetic Information with High-Density DNA Arrays , 1996, Science.